IDNA - ETF AI Analysis
Top Page
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA)
Rating:59Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past month, indicating positive recent momentum.
High-Growth Top Holdings
Several of the largest positions, including companies like Moderna, Revolution Medicines, and Twist Bioscience, have delivered strong year-to-date gains that support the fund’s overall performance.
Global Healthcare Exposure
While most holdings are in the U.S., the fund also invests in healthcare companies across Europe and Asia, adding some international diversification within the sector.
Negative Factors
Sector Concentration Risk
With the vast majority of assets in healthcare and related areas, the ETF is heavily exposed to downturns or policy changes affecting this single sector.
Thematic and Niche Focus
Its narrow focus on genomics, immunology, and specialized healthcare means performance can be more volatile and sensitive to sentiment around these specific themes.
Above-Average Expense Ratio
The fund’s fee is higher than many broad market ETFs, which slightly reduces the net return investors keep over time.
IDNA vs. SPDR S&P 500 ETF (SPY)
AUM201.14M
RegionGlobal
Expense Ratio0.47%
Beta0.88
IssueriShares
Inception DateJun 11, 2019
Dividend Yield0.84%
Asset ClassEquity
Index TrackedNYSE FactSet Global Genomics and Immuno Biopharma Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume89,598
30 Day Avg. Volume51,178
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.23Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDNA Summary
IDNA is the iShares Genomics Immunology and Healthcare ETF, which follows the NYSE FactSet Global Genomics and Immuno Biopharma Index. It invests in companies working on gene-based medicine, advanced drug research, and new healthcare treatments. Well-known holdings include Moderna and Merck, along with other biotech and pharmaceutical firms from the U.S. and around the world. Someone might invest in IDNA to seek long-term growth from breakthroughs in genomics and cutting-edge healthcare. However, this ETF is heavily focused on a single, high-risk sector, so its price can swing sharply and may fall if biotech stocks struggle.
How much will it cost me?The iShares Genomics Immunology and Healthcare ETF (IDNA) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires active management to track innovative companies in genomics and healthcare. The higher cost reflects the specialized nature of the fund.
What would affect this ETF?The IDNA ETF, focused on genomics and healthcare innovation, could benefit from advancements in gene editing, personalized medicine, and increased global healthcare spending, which may drive growth in its top holdings like Revolution Medicines and Regeneron. However, it faces risks from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector, which could impact the performance of companies within the fund. Global economic conditions and changes in government healthcare policies could also influence the ETF's future performance.
IDNA Top 10 Holdings
IDNA is a pure play on cutting-edge biotech, with its top holdings clustered in genomics and immunotherapy rather than broad healthcare. U.S. names like Twist Bioscience and Moderna are doing much of the heavy lifting, with their stocks rising on optimism around next‑generation therapies despite ongoing losses. Vertex and Incyte add a steadier, more profitable backbone, helping smooth out volatility. On the flip side, BioNTech and global pharma giants like Bayer and Japan’s Takeda have been lagging, acting as a bit of a brake on this otherwise innovation‑driven, globally diversified portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 5.86% | $11.73M | $31.65B | 151.38% | 59 Neutral | |
| Twist Bioscience | 4.90% | $9.82M | $6.18B | 180.78% | 43 Neutral | |
| Bayer | 4.74% | $9.49M | €52.42B | 92.14% | 54 Neutral | |
| Revolution Medicines | 4.32% | $8.66M | $40.23B | 418.11% | 52 Neutral | |
| Vertex Pharmaceuticals | 4.02% | $8.06M | $134.02B | 11.98% | 78 Outperform | |
| ― | 3.87% | $7.74M | ― | ― | ― | |
| Incyte | 3.84% | $7.68M | $23.35B | 74.45% | 81 Outperform | |
| Takeda Pharmaceutical Co | 3.73% | $7.48M | ¥8.50T | 13.92% | 66 Neutral | |
| BioNTech SE | 3.62% | $7.25M | $24.67B | -14.65% | 53 Neutral | |
| Ipsen | 3.62% | $7.25M | €14.12B | 64.05% | 70 Outperform |
IDNA Technical Analysis
Positive
―
Price Trends
30.49
Positive
30.04
Positive
28.12
Positive
Market Momentum
1.25
Negative
61.97
Neutral
61.81
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDNA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.32, equal to the 50-day MA of 30.49, and equal to the 200-day MA of 28.12, indicating a bullish trend. The MACD of 1.25 indicates Negative momentum. The RSI at 61.97 is Neutral, neither overbought nor oversold. The STOCH value of 61.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDNA.
IDNA Peer Comparison
Comparison Results
Performance Comparison
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
33.55
12.57
59.91%
IHAK
iShares Cybersecurity & Tech ETF
―
―
―
GII
SPDR S&P Global Infrastructure ETF
―
―
―
UFO
Procure Space ETF
―
―
―
NUKZ
Range Nuclear Renaissance Index ETF
―
―
―
MGNR
American Beacon GLG Natural Resources ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents